IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Purchased by Cardinal Capital Management

Cardinal Capital Management grew its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 0.3% in the 4th quarter, Holdings Channel.com reports. The fund owned 13,954 shares of the company’s stock after purchasing an additional 35 shares during the quarter. Cardinal Capital Management’s holdings in IDEXX Laboratories were worth $5,769,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of IDXX. Angeles Wealth Management LLC lifted its holdings in shares of IDEXX Laboratories by 2.4% during the third quarter. Angeles Wealth Management LLC now owns 1,078 shares of the company’s stock valued at $545,000 after purchasing an additional 25 shares during the last quarter. Cranbrook Wealth Management LLC raised its stake in IDEXX Laboratories by 7.0% during the 4th quarter. Cranbrook Wealth Management LLC now owns 382 shares of the company’s stock valued at $158,000 after purchasing an additional 25 shares during the period. Perigon Wealth Management LLC lifted its holdings in shares of IDEXX Laboratories by 1.8% in the fourth quarter. Perigon Wealth Management LLC now owns 1,474 shares of the company’s stock valued at $632,000 after purchasing an additional 26 shares in the last quarter. Summit Trail Advisors LLC boosted its position in shares of IDEXX Laboratories by 3.3% in the fourth quarter. Summit Trail Advisors LLC now owns 810 shares of the company’s stock worth $335,000 after buying an additional 26 shares during the period. Finally, First Horizon Advisors Inc. grew its holdings in shares of IDEXX Laboratories by 4.0% during the third quarter. First Horizon Advisors Inc. now owns 704 shares of the company’s stock valued at $356,000 after buying an additional 27 shares in the last quarter. Institutional investors own 87.84% of the company’s stock.

Wall Street Analyst Weigh In

IDXX has been the subject of several research analyst reports. Bank of America increased their price objective on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 4th. Barclays boosted their price objective on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a research report on Tuesday, February 4th. Leerink Partnrs upgraded shares of IDEXX Laboratories to a “strong-buy” rating in a research note on Monday, December 2nd. Leerink Partners assumed coverage on shares of IDEXX Laboratories in a research note on Monday, December 2nd. They set an “outperform” rating and a $500.00 target price for the company. Finally, Morgan Stanley dropped their price target on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 29th. Four analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $533.75.

Insider Buying and Selling at IDEXX Laboratories

In related news, Director Sophie V. Vandebroek sold 344 shares of the company’s stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total transaction of $144,631.36. Following the completion of the sale, the director now directly owns 905 shares of the company’s stock, valued at approximately $380,498.20. This represents a 27.54 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction on Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the completion of the transaction, the director now owns 3,061 shares in the company, valued at $1,426,242.34. This trade represents a 49.50 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 13,330 shares of company stock worth $6,161,276 over the last three months. Corporate insiders own 2.11% of the company’s stock.

IDEXX Laboratories Stock Down 3.3 %

IDEXX Laboratories stock opened at $444.53 on Tuesday. The company has a market capitalization of $36.40 billion, a P/E ratio of 41.66, a P/E/G ratio of 3.47 and a beta of 1.37. IDEXX Laboratories, Inc. has a 1-year low of $398.50 and a 1-year high of $583.39. The firm’s fifty day simple moving average is $430.95 and its 200-day simple moving average is $452.80. The company has a current ratio of 1.31, a quick ratio of 1.03 and a debt-to-equity ratio of 0.28.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.